STOCK TITAN

Azenta (AZTA) Stock Price, News & Analysis

AZTA NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
39 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
-25.3% close of May 6, 2026
1-year change
+65.5% closing prices, November 18, 2025 to November 18, 2026
1-month change
+42.8% closing prices, October 16, 2026 to November 18, 2026

Company Description

Azenta, Inc. (Nasdaq: AZTA), also known as Azenta Life Sciences, is a provider of life sciences solutions that help organizations bring breakthroughs and therapies to market faster. According to company disclosures, Azenta focuses on cold-chain sample management and multiomics services, supporting work in areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions.

Azenta is headquartered in Burlington, Massachusetts, and reports that it has operations in North America, Europe and Asia. The company’s common stock trades on Nasdaq under the ticker symbol AZTA. Its activities place it within the broader manufacturing and technology ecosystem that supports the life sciences industry, with a particular emphasis on sample management infrastructure and genomic and other multiomics analysis.

Business focus and segments

Based on available information, Azenta organizes its operations around two primary areas: Sample Management Solutions and Multiomics.

  • Sample Management Solutions – In public materials, Azenta describes a "full suite of reliable cold-chain sample management solutions" and references biorepository facilities and sample storage. The company highlights capabilities in secure storage and logistics for biological samples, including support for clinical and diagnostic research. Sample Management Solutions includes offerings such as sample storage and repository services, and the company has referenced biorepository operations, including a facility in Indianapolis, Indiana.
  • Multiomics – Azenta states that it provides multiomics services, including genomic analysis. Through its GENEWIZ brand, the company delivers genomic sequencing services. Company disclosures reference activities such as next generation sequencing, gene synthesis and other genomic analysis services, which are reported within the Multiomics segment.

In financial reports, Azenta distinguishes between products and services revenue, with services including activities such as genomic services and sample storage, and products including items such as consumables and instruments that support sample management workflows. The company’s segment reporting identifies Sample Management Solutions and Multiomics as key contributors to revenue.

Sample management and cold-chain capabilities

Azenta emphasizes its role in cold-chain sample management, supporting the storage and handling of temperature-sensitive biological and chemical samples. Public statements describe a focus on reliable cold-chain solutions and biorepository services that help maintain sample integrity for research and clinical programs. The company notes that it provides secure storage of study samples and manages logistics for research collaborations, such as its partnership with the PRECEDE Foundation for early detection of pancreatic cancer.

Azenta’s sample management capabilities are positioned to support large-scale research initiatives and clinical programs that require long-term storage and tracking of biospecimens. The company highlights its "global biorepository network" in connection with collaborations and indicates that it manages sample storage for complex, multi-institutional research efforts.

Multiomics and genomic services

Through its Multiomics segment, Azenta offers genomic analysis services that support precision medicine and research. Company communications describe activities such as next generation sequencing and gene synthesis, and reference partnerships where Azenta, via GENEWIZ, provides genomic sequencing and data generation. These services are used in research programs focused on diseases such as kidney and cardio-kidney-metabolic conditions, as well as oncology-focused initiatives like the PRECEDE Foundation’s work in pancreatic cancer.

Azenta reports that growth in its Multiomics segment has been driven in part by increased revenue from next generation sequencing, while noting variability in other sequencing modalities such as Sanger sequencing and gene synthesis. The company positions its multiomics capabilities as part of a broader offering that combines sequencing, data generation and sample management.

Brands and global reach

Azenta states that it delivers and supports its products and services through a set of industry-recognized brands, including:

  • GENEWIZ
  • FluidX
  • Ziath
  • 4titude
  • Limfinity
  • Freezer Pro
  • Barkey

These brands are associated with areas such as genomic services, sample management tools, informatics and cold-chain solutions, according to company descriptions. Azenta notes that its customer base includes top pharmaceutical and biotech companies, academic institutions and healthcare organizations globally, reflecting its presence across major life sciences markets in North America, Europe and Asia.

Corporate activity and portfolio

Azenta’s public disclosures show ongoing portfolio management and capital allocation decisions. The company announced a definitive agreement for the sale of its B Medical Systems business to THELEMA S.À R.L., describing this as a step toward simplifying its portfolio and prioritizing core capabilities. It has also authorized a share repurchase program, indicating a focus on returning capital to shareholders alongside investments in productivity, organic growth and selective mergers and acquisitions.

Financial updates highlight the performance of the Sample Management Solutions and Multiomics segments, with commentary on revenue trends, gross margin, adjusted EBITDA and operating expenses. Azenta has reported efforts to streamline its organization, improve cost execution and enhance productivity through what it calls the Azenta Business System.

Governance and shareholder engagement

Azenta files regular reports and proxy statements with the U.S. Securities and Exchange Commission. Its definitive proxy statement outlines matters such as the election of directors, advisory votes on executive compensation, amendments to equity incentive plans and the ratification of independent auditors. The company holds an annual meeting of shareholders, conducted in a virtual format according to recent proxy materials, and provides for voting by mail, telephone and internet.

The proxy statement also describes the structure of the Board of Directors, board committees, risk oversight, environmental, social and governance (ESG) considerations and executive compensation programs. These disclosures provide investors with information on how Azenta approaches governance, compensation and long-term value creation.

Role in the life sciences ecosystem

According to its public communications, Azenta positions itself as a partner to organizations engaged in high-impact life science research and development. By combining cold-chain sample management, biorepository services and multiomics capabilities, the company aims to support the development of diagnostics, therapies and precision medicine approaches. Its collaborations with foundations, medical centers and industry partners illustrate how its infrastructure and services are integrated into large-scale research programs.

Stock Performance

$49.64
+1.95%
+0.95
After hoursChange vs the $48.69 closeLast updated: at
+65.5%
Performance 1 year

Azenta (AZTA) closed at $48.69 on November 18, 2026. Over the past 12 months, the price has gained 65.5%.

See what a $1,000 investment in AZTA would be worth today

Average down calculator for AZTA

AZTA Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Azenta has 10 recent news articles, with the latest published on . Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include conferences, management, earnings. View all AZTA news →

Financial Highlights

Azenta generated $593.8M in revenue in FY2025, retaining a 45.5% gross margin, operating income reached -$26.8M (-4.5% operating margin), and net income was -$55.8M, reflecting a -9.4% net profit margin. Diluted earnings per share stood at -$1.22. The company generated $72.2M in operating cash flow. The current ratio was 2.98, measuring current assets divided by current liabilities.

$593.8M
Revenue (FY2025)
-$55.8M
Net Income (FY2025)
$72.2M
Operating Cash Flow

Upcoming Events

NOV
30
November 30, 2026 Marketing

Evercore fireside chat

Fireside chat at Evercore Healthcare Conference on Nov 30, 2026 at 2:10 pm ET; live webcast on Azenta, Inc. investor relations; replay available.

Azenta has 1 upcoming scheduled event. The next event, "Evercore fireside chat", is scheduled for November 30, 2026 (in 12 days). Investors can track these dates to stay informed about potential catalysts that may affect the AZTA stock price.

Short Interest History

Last 12 Months

Short interest in Azenta (AZTA) currently stands at 5.4 million shares, up 0.8% from the previous reporting period, representing 13.2% of the float. Since November 2025, short interest has increased by 60.9%.

Days to Cover History

Last 12 Months

Days to cover for Azenta (AZTA) currently stands at 6.2 days, up 79.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 53.8%. Across the settlements charted above, it has ranged from 3.5 to 9.9 days.

AZTA Company Profile & Sector Positioning

Azenta (AZTA) operates in the Medical Instruments & Supplies industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing AZTA often look at related companies in the same sector, including DENTSPLY SIRONA Inc. (XRAY), LeMaitre Vascular, Inc. (LMAT), Kestra Medical Technologies, Ltd. (KMTS), Staar Surgical Co (STAA), and AngioDynamics, Inc. (ANGO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate AZTA's relative position within its industry.

Frequently Asked Questions

The current stock price of Azenta (AZTA) is $49.64 in after-hours trading as of November 18, 2026.

The market cap of Azenta (AZTA) is approximately $2.1B. Learn more about what market capitalization means .

The FY2025 revenue of Azenta (AZTA) is $593.8M, from its most recent completed fiscal year.

The FY2025 net income of Azenta (AZTA) is -$55.8M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Azenta (AZTA) is -$1.22 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Azenta (AZTA) is $72.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Azenta (AZTA) is -9.4% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Azenta (AZTA) is -4.5% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Azenta (AZTA) is 45.5% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Azenta (AZTA), current assets divided by current liabilities, was 2.98 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Azenta (AZTA) is $270.3M for FY2025, its most recent completed fiscal year.

The operating income of Azenta (AZTA) is -$26.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

Azenta, Inc. is a life sciences company that provides cold-chain sample management solutions and multiomics services to support drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions.

Azenta reports two primary segments: Sample Management Solutions, which focuses on sample storage and related offerings, and Multiomics, which provides genomic and other multiomics analysis services.

Azenta’s Multiomics segment offers genomic analysis services, including next generation sequencing and gene synthesis, delivered through brands such as GENEWIZ to support research and precision medicine initiatives.

Cold-chain sample management refers to Azenta’s focus on reliable storage and handling of temperature-sensitive biological and chemical samples, including biorepository services and logistics that help maintain sample integrity for research and clinical programs.

Azenta reports that it is headquartered in Burlington, Massachusetts, and has operations in North America, Europe and Asia, serving customers in major life sciences markets.

Azenta delivers its products and services through brands including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro and Barkey, which cover areas such as genomic services, sample management tools and informatics.

Azenta’s common stock is listed on the Nasdaq stock market under the ticker symbol AZTA.

Azenta has disclosed a definitive agreement to sell its B Medical Systems business to THELEMA S.À R.L., describing the sale as a step toward simplifying its portfolio and focusing on core capabilities.

According to company statements, Azenta serves top pharmaceutical and biotech companies, academic institutions and healthcare organizations that rely on sample management and multiomics services for research and clinical applications.

In collaborations such as those with the PRECEDE Foundation and Frenova and Nephronomics, Azenta describes its role as providing secure sample storage, biorepository services and genomic sequencing to support large-scale research and precision medicine programs.